A Toxic Scandal Rocks Sri Lanka's Healthcare System: Was This Deadly Drug Cleared Too Easily?
A recent revelation by Dr. Chamal Sanjeewa, Chairman of the Doctors' Trade Union Alliance for Medical and Civil Rights, has sent shockwaves through Sri Lanka's healthcare sector. He claims the Ondansetron Injection, later found to contain a bacterial toxin, was initially cleared by laboratory tests before importation. But here's where it gets controversial: Dr. Sanjeewa insists the original samples showed no signs of toxicity, raising serious questions about the reliability of the testing process and the potential for systemic failures within the country's drug regulatory system.
Dr. Sanjeewa revealed that the importing company brought the drug into Sri Lanka on four separate occasions, with batches manufactured in India in 2024 and 2025. Each shipment, totaling 67,600 vials per batch, was supposedly tested in Indian laboratories before being shipped. These tests, according to Dr. Sanjeewa, covered ten different criteria, including pH value, appearance, composition, and crucially, bacterial toxicity. The company reportedly informed Sri Lanka's Drug Regulatory Authority that all tests were passed.
But if the initial tests were accurate, how did a contaminated batch slip through the cracks? Dr. Sanjeewa warns that simply accepting Indian test results again after the drug arrives in Sri Lanka would be a devastating blow to public trust in the healthcare system. He demands legal action against those responsible for this debacle, arguing that it highlights a deeper issue of poor health administration eroding public confidence.
And this is the part most people miss: Dr. Sanjeewa points out that Sri Lanka's own Quality Control Laboratory lacks accreditation from the Sri Lanka Accreditation Body (SLAB). Establishing a fully equipped, internationally recognized lab, he argues, would cost a relatively modest Rs. 5 billion – a small price to pay compared to the potential cost of lives and public funds lost due to substandard medicines.
This scandal raises crucial questions: Are Sri Lanka's drug regulations robust enough? Can we rely solely on foreign testing? Should more resources be invested in strengthening our own quality control infrastructure? Dr. Sanjeewa's call for accountability and system reform is a wake-up call. The health and safety of Sri Lankans depend on it. What do you think? Is enough being done to ensure the safety of our medicines? Let us know in the comments below.
